Pleura and Peritoneum (Jun 2022)

Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design

  • Raoof Mustafa,
  • Sullivan Kevin M.,
  • Frankel Paul H.,
  • Fakih Marwan,
  • Synold Timothy W.,
  • Lim Dean,
  • Woo Yanghee,
  • Paz Isaac Benjamin,
  • Fong Yuman,
  • Thomas Rebecca Meera,
  • Chang Sue,
  • Eng Melissa,
  • Tinsley Raechelle,
  • Whelan Richard L.,
  • Deperalta Danielle,
  • Reymond Marc A.,
  • Jones Jeremy,
  • Merchea Amit,
  • Dellinger Thanh H.

DOI
https://doi.org/10.1515/pp-2022-0116
Journal volume & issue
Vol. 7, no. 4
pp. 169 – 177

Abstract

Read online

Peritoneal metastasis (PM) from appendiceal cancer or colorectal cancer (CRC) has significant morbidity and limited survival. Pressurized intraperitoneal aerosolized chemotherapy (PIPAC) is a minimally invasive approach to treat PM. We aim to conduct a dose-escalation trial of mitomycin C (MMC)-PIPAC combined with systemic chemotherapy (FOLFIRI) in patients with PM from appendiceal cancer or CRC.

Keywords